Diabetic kidney disease remains a leading cause of end-stage renal disease globally, placing an immense clinical burden on healthcare systems. Although intensive glycemic and blood pressure management delay disease onset, renal injury often progresses relentlessly in high-risk patients. Therefore, researchers are investigating injury-amplifying mechanisms that extend beyond conventional metabolic and hemodynamic pathways. Recently, ferroptosis in DKD has emerged as a crucial driver of progressive nephron destruction and functional deterioration.

Understanding the Role of Ferroptosis in DKD Pathogenesis

Ferroptosis represents a unique, non-apoptotic form of regulated cell death driven by iron-catalyzed lipid peroxidation. In diabetic kidneys, persistent hyperglycemia disrupts normal cellular respiration and accelerates the production of reactive oxygen species. Consequently, tubular epithelial cells experience severe oxidative damage, which overwhelms endogenous cytoprotective mechanisms. Specifically, the downregulation of glutathione peroxidase 4 compromises the reduction of toxic lipid hydroperoxides within plasma and organelle membranes. In addition, dysregulated iron metabolism increases intracellular labile iron pools, accelerating toxic Fenton reactions. Acyl-CoA synthetase long-chain family member 4 also enriches cellular membranes with polyunsaturated fatty acids. Therefore, these vulnerable lipids undergo catastrophic peroxidation under persistent metabolic stress. As membrane integrity fails, tubular cells and podocytes suffer irreversible structural damage, culminating in renal architecture loss. Consequently, this cell death cascade accelerates glomerular filtration decline and worsens proteinuria. Preclinical models demonstrate that mitigating iron accumulation directly preserves nephron architecture and delays functional decline. Thus, recognizing this death pathway provides vital biological insights into diabetic nephropathy progression.

Mechanistic Interplay Between Lipid Peroxidation and Immune Activation

Renal ferroptosis does not occur as an isolated parenchymal event. Instead, lipid peroxidation-derived danger signals actively engage the innate immune system to amplify tissue damage. When renal tubular cells undergo ferroptotic disintegration, they release specific damage-associated molecular patterns, such as high mobility group box 1. Consequently, these released biomolecules bind toll-like receptor 4 on resident immune cells, triggering robust inflammatory signaling cascades. Furthermore, lipid electrophiles stimulate neutrophil recruitment and trigger rapid dendritic-cell maturation within renal interstitial spaces. Resident and infiltrating monocytes subsequently polarize into the proinflammatory M1 macrophage phenotype, generating potent cytotoxic molecules. Simultaneously, cytosolic danger signals trigger NLRP3 inflammasome assembly within both immune cells and surviving tubular epithelium. This molecular platform cleaves pro-caspase-1, which drives the maturation and systemic release of interleukin-1beta and interleukin-18. Therefore, the sterile microenvironment rapidly transforms into an active inflammatory battleground. In addition, these innate immune responses disrupt regional microvascular perfusion, exacerbating parenchymal hypoxia. As a result, acute tubular injury easily transitions into chronic tubulointerstitial inflammation, which accelerates renal decline.

The Self-Amplifying Feedback Loop of Renal Inflammation

The crosstalk between ferroptosis and innate immunity establishes a hazardous, self-sustaining pathological circuit within diabetic nephrons. While ferroptotic cells activate immune pathways, inflammatory cytokines reciprocally intensify renal susceptibility to iron-dependent lipid injury. For example, tumor necrosis factor-alpha and interleukin-6 directly impair iron storage proteins, such as ferritin, releasing additional free iron into the cytoplasm. In addition, these inflammatory mediators upregulate transferrin receptor expression, which dramatically increases intracellular iron uptake. Consequently, expanding labile iron pools generate elevated hydroxyl radicals via uncontrolled Fenton chemistry. Moreover, persistent cytokine exposure suppresses nuclear factor erythroid 2-related factor 2 activity, diminishing cellular antioxidant defenses and depleting intracellular glutathione reserves. As glutathione levels plummet, glutathione peroxidase 4 cannot detoxify peroxidized phospholipids effectively. Therefore, surrounding vulnerable epithelial cells and podocytes undergo secondary ferroptotic death. This continuous destruction releases higher concentrations of damage-associated molecular patterns, creating an unyielding cycle of tissue breakdown. Thus, the bidirectional ferroptosis-immunity axis explains why diabetic renal impairment often accelerates despite rigorous glucose control.

Diagnostic Biomarkers for Earlier Stratification

Identifying dependable clinical biomarkers along the ferroptosis-immunity axis holds enormous promise for early diabetic nephropathy detection. Currently, standard clinical parameters like serum creatinine and urinary albumin reflect established structural nephron damage rather than active cellular injury. Therefore, clinicians urgently require dynamic molecular indicators that detect early renal susceptibility. Emerging candidate biomarkers include reduced systemic or urinary levels of glutathione peroxidase 4 and elevated expression of acyl-CoA synthetase long-chain family member 4. In addition, quantified lipid peroxidation byproducts, such as malondialdehyde and 4-hydroxynonenal, reflect ongoing tubular oxidative destruction. Circulating levels of interleukin-18 and high mobility group box 1 may also signal concurrent inflammasome activation and innate immune involvement. However, substantial diagnostic hurdles prevent the immediate clinical implementation of these candidate markers. Most clinical studies remain cross-sectional with small cohorts, lacking standardized assay thresholds and longitudinal human validation. Furthermore, distinguishing kidney-specific ferroptotic markers from systemic vascular inflammation remains an analytical challenge. Overcoming these barriers will allow practitioners to identify vulnerable diabetic individuals before irreversible renal filtration decline occurs.

Emerging Therapeutic Strategies and Future Clinical Directions

Targeting the ferroptosis-immunity axis offers compelling therapeutic opportunities to complement modern glycemic and blood pressure therapies. Researchers are aggressively evaluating selective ferroptosis inhibitors, including liproxstatin-1 and ferrostatin-1, to halt lipid peroxidation cascades. In addition, iron chelators like deferoxamine sequester intracellular labile iron pools, effectively preventing free-radical generation. Novel molecular strategies also focus on activating the nuclear factor erythroid 2-related factor 2 pathway, thereby boosting endogenous glutathione peroxidase 4 activity. Furthermore, immunomodulatory agents targeting toll-like receptor 4 or the NLRP3 inflammasome show remarkable efficacy in disrupting inflammatory propagation. Interestingly, established sodium-glucose cotransporter 2 inhibitors confer renoprotection partially by reducing iron overload and enhancing cellular antioxidant defenses. To optimize systemic safety, bioengineers are designing kidney-targeted nanoparticle delivery systems and exploring CRISPR-based gene modulation of key ferroptotic regulators. Moreover, integrating multiomics profiling with artificial intelligence models will accelerate the discovery of customized combination regimens. Ultimately, combining targeted anti-ferroptotic therapies with optimal glycemic control represents a mechanism-based paradigm to halt diabetic kidney disease progression.

Frequently Asked Questions

What differentiates ferroptosis from other forms of cell death in diabetic nephropathy?

Ferroptosis represents an iron-dependent, non-apoptotic regulated cell death process driven specifically by overwhelming lipid peroxidation on cellular membranes. Unlike apoptosis, which relies on caspase cascades and cellular shrinkage, ferroptosis involves severe mitochondrial morphological alterations and plasma membrane rupture. Furthermore, unlike passive necrosis, ferroptosis follows an organized metabolic pathway controlled by glutathione peroxidase 4 and iron regulatory networks, making it pharmacologically modifiable in diabetic kidney disease.

How does the innate immune system interact with ferroptosis in diabetic kidneys?

Dying ferroptotic renal tubular cells release potent damage-associated molecular patterns, particularly high mobility group box 1, into the interstitial space. Consequently, these molecules activate toll-like receptor 4 and stimulate NLRP3 inflammasomes within macrophages and dendritic cells. Activated immune cells secrete inflammatory cytokines, including interleukin-18, which alter systemic iron transport and trigger further reactive oxygen species generation. This vicious crosstalk amplifies tubular injury and drives chronic progressive renal fibrosis.

Do existing diabetic kidney disease medications influence the ferroptosis pathway?

Recent pharmacological evidence reveals that sodium-glucose cotransporter 2 inhibitors significantly attenuate renal ferroptosis beyond their blood sugar-lowering actions. These agents reduce intracellular iron overload, enhance mitochondrial metabolic efficiency, and stimulate the protective Nrf2 antioxidant signaling cascade. By restoring glutathione peroxidase 4 activity and suppressing toxic lipid peroxidation, sodium-glucose cotransporter 2 inhibitors mitigate tubular cell death. Consequently, these findings highlight why current guideline-directed medical therapies demonstrate such powerful renoprotective benefits in clinical trials.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Zhang W et al. The Ferroptosis-Immunity Axis in Diabetic Kidney Disease: Emerging Therapeutic Targets. Antioxid Redox Signal. 2026 Sep 02. doi: 10.1177/15230864261483982. PMID: 42686659.

Wu Q, Huang F. Targeting ferroptosis as a prospective therapeutic approach for diabetic nephropathy. Ann Med. 2024;56(1):2346543.

Li S, et al. Crosstalk between ferroptosis and innate immune in diabetic kidney disease: mechanisms and therapeutic implications. Front Immunol. 2025;16:1505794.